Is DSS, Inc. (DSS) a Buy, Sell, or Hold?
AMEX : DSS
DSS, Inc.
$0.5999 USD
$0.02 (3.08%)
- Volume
- 49.71K
- Average Volume
- 1.51M
- Market Capitalization
- $5.09M
- P/E Ratio
- -0.22
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.90
- Year Low
- $0.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.22
| Source | Headline |
|---|---|
|
DSS, Inc. Withdraws Registration Statement
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. After careful review of current market conditions and deal terms, management and the Board of Directors concluded that proceeding with the offering at this time would not reflect the value DSS believes it is building for shareholders. globenewswire.com - 2026-06-09 10:15:00 |
|
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte gurufocus.com - 2026-05-19 21:00:00 |
|
DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025. globenewswire.com - 2026-05-08 17:00:00 |
